MAPT and Alzheimer disease: Notably, P(AD) was consistently higher in Aβ, tau, and FDG PET positive groups, demonstrating that our framework’s diagnostic process aligns well with the current amyloid, tau, and neurodegeneration (ATN) criteria for AD diagnosis.43 Within the NACC cohort, FTD probabilities, P(FTD), were significantly associated with MRI and FDG PET biomarkers, with the biomarker positive groups having higher P(FTD).